Age-Related Changes of Peak Width Skeletonized Mean Diffusivity (PSMD) Across the Adult Lifespan: A Multi-Cohort Study.

MRI PSMD ageing diffusion neurodegeneration white matter

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2020
Historique:
received: 06 01 2020
accepted: 06 04 2020
entrez: 20 5 2020
pubmed: 20 5 2020
medline: 20 5 2020
Statut: epublish

Résumé

Parameters of water diffusion in white matter derived from diffusion-weighted imaging (DWI), such as fractional anisotropy (FA), mean, axial, and radial diffusivity (MD, AD, and RD), and more recently, peak width of skeletonized mean diffusivity (PSMD), have been proposed as potential markers of normal and pathological brain ageing. However, their relative evolution over the entire adult lifespan in healthy individuals remains partly unknown during early and late adulthood, and particularly for the PSMD index. Here, we gathered and analyzed cross-sectional diffusion tensor imaging (DTI) data from 10 population-based cohort studies in order to establish the time course of white matter water diffusion phenotypes from post-adolescence to late adulthood. DTI data were obtained from a total of 20,005 individuals aged 18.1 to 92.6 years and analyzed with the same pipeline for computing skeletonized DTI metrics from DTI maps. For each individual, MD, AD, RD, and FA mean values were computed over their FA volume skeleton, PSMD being calculated as the 90% peak width of the MD values distribution across the FA skeleton. Mean values of each DTI metric were found to strongly vary across cohorts, most likely due to major differences in DWI acquisition protocols as well as pre-processing and DTI model fitting. However, age effects on each DTI metric were found to be highly consistent across cohorts. RD, MD, and AD variations with age exhibited the same U-shape pattern, first slowly decreasing during post-adolescence until the age of 30, 40, and 50 years, respectively, then progressively increasing until late life. FA showed a reverse profile, initially increasing then continuously decreasing, slowly until the 70s, then sharply declining thereafter. By contrast, PSMD constantly increased, first slowly until the 60s, then more sharply. These results demonstrate that, in the general population, age affects PSMD in a manner different from that of other DTI metrics. The constant increase in PSMD throughout the entire adult life, including during post-adolescence, indicates that PSMD could be an early marker of the ageing process.

Identifiants

pubmed: 32425831
doi: 10.3389/fpsyt.2020.00342
pmc: PMC7212692
doi:

Types de publication

Journal Article

Langues

eng

Pagination

342

Subventions

Organisme : Medical Research Council
ID : MR/R024065/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N027558/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701120
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0700704
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M013111/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1001245
Pays : United Kingdom

Informations de copyright

Copyright © 2020 Beaudet, Tsuchida, Petit, Tzourio, Caspers, Schreiber, Pausova, Patel, Paus, Schmidt, Pirpamer, Sachdev, Brodaty, Kochan, Trollor, Wen, Armstrong, Deary, Bastin, Wardlaw, Munõz Maniega, Witte, Villringer, Duering, Debette and Mazoyer.

Références

NMR Biomed. 2019 Apr;32(4):e3841
pubmed: 29193413
Neuroimage. 2016 Mar;128:180-192
pubmed: 26724777
PLoS One. 2017 Nov 16;12(11):e0187600
pubmed: 29145428
Neuroimage. 2010 May 1;50(4):1376-83
pubmed: 20109562
Neuroimage. 2014 Jul 15;95:136-50
pubmed: 24657781
Hum Brain Mapp. 2019 Jun 1;40(8):2305-2319
pubmed: 30666760
J Neurosci. 2011 Jul 27;31(30):10937-47
pubmed: 21795544
Magn Reson Med. 2017 Nov;78(5):1767-1780
pubmed: 28090658
Hum Brain Mapp. 2010 Mar;31(3):378-90
pubmed: 19662658
Neuroimage. 2011 Feb 1;54(3):1840-53
pubmed: 20932911
J Neurosci. 2014 Nov 12;34(46):15425-36
pubmed: 25392509
Neuroimage. 2008 Apr 15;40(3):1044-55
pubmed: 18295509
Neurobiol Aging. 2018 Nov;71:161-170
pubmed: 30145396
Neurobiol Aging. 2015 Sep;36(9):2563-7
pubmed: 26059713
Neuroimage. 2010 Jan 1;49(1):94-103
pubmed: 19679191
Cereb Cortex. 2010 Sep;20(9):2055-68
pubmed: 20032062
Brain Struct Funct. 2010 May;214(4):361-73
pubmed: 20127357
PLoS One. 2015 Oct 12;10(10):e0137905
pubmed: 26457415
Biol Psychiatry. 2012 Dec 15;72(12):1026-34
pubmed: 23017471
Neuroimage. 2017 Nov 1;161:149-170
pubmed: 28826946
Neuroimage. 2011 Sep 1;58(1):41-9
pubmed: 21640837
Front Psychiatry. 2019 Jul 26;10:524
pubmed: 31402877
Front Hum Neurosci. 2017 Aug 07;11:393
pubmed: 28824398
Neuroimage. 2016 Apr 15;130:194-213
pubmed: 26872408
Magn Reson Med. 2009 Apr;61(4):755-60
pubmed: 19191286
Front Neuroinform. 2019 Feb 19;13:2
pubmed: 30837858
Biol Psychiatry. 2019 Nov 15;86(10):759-768
pubmed: 31443934
Proc SPIE Int Soc Opt Eng. 2016 Feb 27;9788:
pubmed: 27350723
Neuroimage. 2013 Nov 1;81:455-469
pubmed: 23629049
NMR Biomed. 2015 Apr;28(4):468-85
pubmed: 25802212
Nat Commun. 2016 Dec 15;7:13629
pubmed: 27976682
J Clin Neurol. 2018 Apr;14(2):129-140
pubmed: 29504292
Magn Reson Insights. 2016 Jun 07;9:9-20
pubmed: 27279747
NMR Biomed. 2019 Apr;32(4):e3778
pubmed: 28886240
Neuroimage. 2008 Jan 15;39(2):566-77
pubmed: 17951075
Neuroreport. 2007 Oct 29;18(16):1735-9
pubmed: 17921878
J Neurol. 2019 Jun;266(6):1293-1302
pubmed: 30120563
Front Integr Neurosci. 2019 Jul 17;13:24
pubmed: 31417372
Clin Sci (Lond). 2017 Jun 7;131(12):1361-1373
pubmed: 28487471
Radiology. 2019 Jun;291(3):763-771
pubmed: 31012815
Cereb Cortex. 2018 May 1;28(5):1857-1865
pubmed: 29490013
Front Neurol. 2019 Feb 13;10:81
pubmed: 30814973
Neuroimage. 2012 Mar;60(1):340-52
pubmed: 22178809
Nat Commun. 2014 Sep 17;5:4932
pubmed: 25230200
Neuroreport. 2001 Jan 22;12(1):99-104
pubmed: 11201100
Ann Neurol. 2016 Oct;80(4):581-92
pubmed: 27518166

Auteurs

Grégory Beaudet (G)

Institute of Neurodegenerative Diseases (IMN), CNRS, CEA, Bordeaux, France.
Institute of Neurodegenerative Diseases (IMN), University of Bordeaux, Bordeaux, France.

Ami Tsuchida (A)

Institute of Neurodegenerative Diseases (IMN), CNRS, CEA, Bordeaux, France.
Institute of Neurodegenerative Diseases (IMN), University of Bordeaux, Bordeaux, France.

Laurent Petit (L)

Institute of Neurodegenerative Diseases (IMN), CNRS, CEA, Bordeaux, France.
Institute of Neurodegenerative Diseases (IMN), University of Bordeaux, Bordeaux, France.

Christophe Tzourio (C)

Bordeaux Population Health Research Center, Inserm, Bordeaux, France.

Svenja Caspers (S)

Institute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Juelich, Germany.
Institute for Anatomy I, Medical Faculty, Heinrich Heine University Dusseldorf, Dusseldorf, Germany.

Jan Schreiber (J)

Institute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Juelich, Germany.

Zdenka Pausova (Z)

Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.
Department of Physiology and Nutritional Sciences, University of Toronto, Toronto, ON, Canada.

Yash Patel (Y)

Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.
Department of Physiology and Nutritional Sciences, University of Toronto, Toronto, ON, Canada.

Tomas Paus (T)

Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, ON, Canada.
Departments of Psychology and Psychiatry, University of Toronto, Toronto, ON, Canada.

Reinhold Schmidt (R)

Department of Neurology, Medical University of Graz, Graz, Austria.

Lukas Pirpamer (L)

Department of Neurology, Medical University of Graz, Graz, Austria.

Perminder S Sachdev (PS)

Centre for Healthy Brain Ageing (CHeBA), School of Psychiatry, UNSW Medicine, University of New South Wales, Sydney, NSW, Australia.
Neuropsychiatric Institute, Neuropsychiatric Institute Prince of Wales Hospital, Randwick, NSW, Australia.

Henry Brodaty (H)

Centre for Healthy Brain Ageing (CHeBA), School of Psychiatry, UNSW Medicine, University of New South Wales, Sydney, NSW, Australia.
Neuropsychiatric Institute, Neuropsychiatric Institute Prince of Wales Hospital, Randwick, NSW, Australia.

Nicole Kochan (N)

Centre for Healthy Brain Ageing (CHeBA), School of Psychiatry, UNSW Medicine, University of New South Wales, Sydney, NSW, Australia.
Neuropsychiatric Institute, Neuropsychiatric Institute Prince of Wales Hospital, Randwick, NSW, Australia.

Julian Trollor (J)

Centre for Healthy Brain Ageing (CHeBA), School of Psychiatry, UNSW Medicine, University of New South Wales, Sydney, NSW, Australia.
Neuropsychiatric Institute, Neuropsychiatric Institute Prince of Wales Hospital, Randwick, NSW, Australia.

Wei Wen (W)

Centre for Healthy Brain Ageing (CHeBA), School of Psychiatry, UNSW Medicine, University of New South Wales, Sydney, NSW, Australia.
Neuropsychiatric Institute, Neuropsychiatric Institute Prince of Wales Hospital, Randwick, NSW, Australia.

Nicola J Armstrong (NJ)

Mathematics and Statistics, Murdoch University, Perth, WA, Australia.

Ian J Deary (IJ)

Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom.

Mark E Bastin (ME)

Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom.
Brain Research Imaging Centre, Neuroimaging Sciences, The University of Edinburgh, Edinburgh, United Kingdom.

Joanna M Wardlaw (JM)

Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom.
Brain Research Imaging Centre, Neuroimaging Sciences, The University of Edinburgh, Edinburgh, United Kingdom.

Susana Munõz Maniega (S)

Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom.
Brain Research Imaging Centre, Neuroimaging Sciences, The University of Edinburgh, Edinburgh, United Kingdom.

A Veronica Witte (AV)

Departmet of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.

Arno Villringer (A)

Departmet of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.

Marco Duering (M)

Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.

Stéphanie Debette (S)

Institute of Neurodegenerative Diseases (IMN), University of Bordeaux, Bordeaux, France.
Bordeaux Population Health Research Center, Inserm, Bordeaux, France.
Department of Neurology, Bordeaux University Hospital, Bordeaux, France.

Bernard Mazoyer (B)

Institute of Neurodegenerative Diseases (IMN), CNRS, CEA, Bordeaux, France.
Institute of Neurodegenerative Diseases (IMN), University of Bordeaux, Bordeaux, France.

Classifications MeSH